TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

GlobeNewswire Inc. Logo GlobeNewswire Inc. By The Schall Law Firm
ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm

Alector's Phase 3 clinical trial for latozinemab in frontotemporal dementia failed to meet primary endpoints, causing a 50% stock price drop and triggering a potential shareholder lawsuit.

Insights
ALEC   negative

Failed clinical trial for key drug candidate, significant stock price decline, and potential legal action from shareholders indicate substantial negative business impact